Literature DB >> 28161553

Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer.

Payal D Soni1, Philip S Boonstra2, Matthew J Schipper3, Latifa Bazzi1, Robert T Dess1, Martha M Matuszak1, Feng-Ming Kong4, James A Hayman1, Randall K Ten Haken1, Theodore S Lawrence1, Gregory P Kalemkerian5, Shruti Jolly6.   

Abstract

INTRODUCTION: Most patients with lung cancer are elderly and poorly represented in randomized clinical trials. They are often undertreated because of concerns about their ability to tolerate aggressive treatment. We tested the hypothesis that elderly patients undergoing definitive lung radiation might tolerate treatment differently than younger patients.
METHODS: A total of 125 patients who underwent definitive lung radiotherapy were identified from a prospective institutional database (University of Michigan cohort). Logistic regression modeling was performed to assess the impact of age on esophagitis grade 2 or higher or grade 2 or higher and pneumonitis grade 3 or higher or grade 2 or higher, with adjustment for esophageal and lung dose, respectively, as well as for chemotherapy utilization, smoking status, and performance status. The analysis was validated in a large cohort of 691 patients from the Michigan Radiation Oncology Quality Consortium registry, an independent statewide prospective database.
RESULTS: In the University of Michigan cohort, multivariable regression models revealed a significant inverse correlation between age and rate of esophagitis for both toxicity levels, (adjusted OR = 0.93 for both models and 95% confidence intervals of 0.88-0.98 and 0.87-0.99), with areas under the curve of 0.747 and 0.721, respectively, demonstrating good fit. This same association was noted in the Michigan Radiation Oncology Quality Consortium cohort. There was no significant association between age and pneumonitis.
CONCLUSIONS: There is a lower incidence of esophagitis with increasing age even after adjustment for use of chemotherapy. This is a novel finding in thoracic oncology. No age dependence was noted for pulmonary toxicity. The elderly are able to tolerate definitive thoracic radiation well and should be offered this option when clinically warranted.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Elderly; Esophagitis; Lung Cancer; Radiation; Toxicity

Mesh:

Year:  2017        PMID: 28161553      PMCID: PMC5318286          DOI: 10.1016/j.jtho.2016.11.2227

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  29 in total

1.  Radiotherapy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival.

Authors:  F Lonardi; M Coeli; G Pavanato; F Adami; G Gioga; F Campostrini
Journal:  Lung Cancer       Date:  2000-04       Impact factor: 5.705

Review 2.  Cancer and aging. An evolving panorama.

Authors:  L Balducci; M Extermann
Journal:  Hematol Oncol Clin North Am       Date:  2000-02       Impact factor: 3.722

3.  Age has no impact on acute and late toxicity of curative thoracic radiotherapy.

Authors:  T Pignon; A Gregor; C Schaake Koning; A Roussel; M Van Glabbeke; P Scalliet
Journal:  Radiother Oncol       Date:  1998-03       Impact factor: 6.280

4.  Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity.

Authors:  Wen-Bo Qiao; Yan-Hui Zhao; Yan-Bin Zhao; Rui-Zhi Wang
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

5.  Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer.

Authors:  Amy J Davidoff; James F Gardner; Brian Seal; Martin J Edelman
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

6.  How does older age influence oncologists' cancer management?

Authors:  Jill A Foster; Gregory D Salinas; Dorcas Mansell; James C Williamson; Linda L Casebeer
Journal:  Oncologist       Date:  2010-05-23

7.  The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer.

Authors:  H Quon; F A Shepherd; D G Payne; P Coy; N Murray; R Feld; J Pater; A Sadura; B Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-01       Impact factor: 7.038

8.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.

Authors:  Jeffrey Bradley; Joseph O Deasy; Soeren Bentzen; Issam El-Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

Review 9.  Cancer in the elderly.

Authors:  Nathan A Berger; Panos Savvides; Siran M Koroukian; Eva F Kahana; Gary T Deimling; Julia H Rose; Karen F Bowman; Robert H Miller
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

10.  Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?

Authors:  Adrian G Sacher; Lisa W Le; Natasha B Leighl; Linda E Coate
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

View more
  3 in total

Review 1.  Non-stereotactic radiotherapy in older cancer patients.

Authors:  Silvana Parisi; Sara Lillo; Alberto Cacciola; Gianluca Ferini; Vito Valenti; Anna Viola; Anna Santacaterina; Angelo Platania; Anna Brogna; Consuelo Tamburella; Stefano Pergolizzi
Journal:  Heliyon       Date:  2022-05-31

2.  Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Shijie Shang; Ruiyang Wang; Fei Wang; Meng Wu; Dawei Chen; Jinming Yu
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 3.  The Role of Radiation Therapy in the Older Patient.

Authors:  Ammoren Dohm; Roberto Diaz; Ronica H Nanda
Journal:  Curr Oncol Rep       Date:  2021-01-02       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.